Menten AI

About:

Menten AI develops peptide and protein therapeutics using machine learning and quantum computing.

Website: http://menten.ai/

Twitter/X: menten_ai

Top Investors: Khosla Ventures, Y Combinator, Sahin Boydas, Creative Destruction Lab (CDL), Uncork Capital

Description:

Menten AI designs new protein drugs and enzymes using quantum computers and machine learning. Proteins are large molecules that can twist into many shapes. Discovering the right shape for a protein to be a drug or a biocatalyst among almost endless possibilities is a major challenge. Menten AI solves this problem by using machine learning and quantum computing to find better starting points for discovery and further development. Quantum computing makes it possible to represent multiple states of the protein simultaneously and efficiently find the best designs. The team created the world’s first peptide designed on a quantum computer and is now working on peptide therapeutics for oncology and neurodegeneration, as well as on enzymes for industrial applications.

Total Funding Amount:

$4.01M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Palo Alto, California, United States

Founded Date:

2018-08-24

Contact Email:

info(AT)menten.ai

Founders:

Hans Melo, Tamas Gorbe, Vikram K. Mulligan

Number of Employees:

1-10

Last Funding Date:

2023-05-05

IPO Status:

Private

Industries:

© 2025 bioDAO.ai